keyword
MENU ▼
Read by QxMD icon Read
search

TMZ

keyword
https://www.readbyqxmd.com/read/28087981/humanized-chondroitinase-abc-sensitizes-glioblastoma-cells-to-temozolomide
#1
Alena Cristina Jaime-Ramirez, Nina Dmitrieva, Ji Young Yoo, Yeshavanth Banasavadi-Siddegowda, Jianying Zhang, Theresa Relation, Chelsea Bolyard-Blessing, Jeffrey Wojton, Balveen Kaur
INTRODUCTION: Malignant gliomas (GBMs) are extremely aggressive and have a median survival of approximately 15 months. Current treatment modalities, which include surgical resection, radiation and chemotherapy, have done little to prolong the lives of GBM patients. Chondroitin sulfate proteoglycans (CSPG) are critical for cell-cell and cell-extra cellular matrix (ECM) interactions and are implicated in glioma growth and invasion. Chondroitinase (Chase) ABC is a bacterial enzyme that cleaves chondroitin sulfate disaccharide chains from CSPGs in the tumor ECM...
January 14, 2017: Journal of Gene Medicine
https://www.readbyqxmd.com/read/28068937/the-efficacy-and-roles-of-combining-temozolomide-with-whole-brain-radiotherapy-in-protection-neurocognitive-function-and-improvement-quality-of-life-of-non-small-cell-lung-cancer-patients-with-brain-metastases
#2
Xia Deng, Zhen Zheng, Baochai Lin, Huafang Su, Hanbin Chen, Shaoran Fei, Zhenghua Fei, Lihao Zhao, Xiance Jin, Cong-Ying Xie
BACKGROUND: Brain metastasis (BM) is a poor prognostic factor for non-small-cell lung cancer (NSCLC). The efficacy and roles of combining temozolomide (TMZ) with whole brain radiotherapy (WBRT) in protection neurocognitive function (NCF) and improvement quality of life (QOL) were investigated and compared with WBRT alone in the treatment of NSCLC patients with BM. METHODS: A total of 238 NSCLC patients with BM were reviewed and categorized into WBRT plus TMZ (RCT) arm and WBRT alone (RT), respectively...
January 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28064447/up-regulation-of-mir-497-confers-resistance-to-temozolomide-in-human-glioma-cells-by-targeting-mtor-bcl-2
#3
Danhua Zhu, Ming Tu, Bo Zeng, Lin Cai, Weiming Zheng, Zhipeng Su, Zhengquan Yu
The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma. Recently, studies have demonstrated that microRNAs play an important role in the regulation of tumor properties in cancers. However, whether miR-497 contributes to glioma resistance to chemotherapy is not fully understood. In this study, we showed that the expression of miR-497 was markedly up-regulated in TMZ-resistant glioma cells; high miR-497 expression level was associated with TMZ-resistant phenotype of glioma cells...
January 8, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28035395/formulation-of-temozolomide-loaded-nanoparticles-and-their-targeting-potential-to-melanoma-cells
#4
Guan Jiang, Ronghua Li, Jianqin Tang, Yafeng Ma, Xiaoyang Hou, Chunsheng Yang, Wenwen Guo, Yong Xin, Yanqun Liu
The present study was carried out to prepare and evaluate a temozolomide (TMZ)-loaded polyamide-amine dendrimer (PAMAM)‑based nanodrug delivery system, and to explore its ability to target human melanoma (A375) cells in vitro. Firstly, PAMAM-PEG and PAMAM-PEG-GE11 were synthesized by substitution and addition reactions, and their products were identified and characterized by fourier transform-infrared (FTIR), proton nuclear magnetic resonance (1H-NMR) and transmission electron microscopy (TEM), as well as differential light scattering (DLS)...
December 29, 2016: Oncology Reports
https://www.readbyqxmd.com/read/28035389/role-of-mir-223-paired-box-6-signaling-in-temozolomide-chemoresistance-in-glioblastoma-multiforme-cells
#5
Quan Cheng, Xiaoqiang Ma, Hui Cao, Zigui Chen, Xin Wan, Rui Chen, Renjun Peng, Jun Huang, Bing Jiang
Glioblastoma (GBM) is the predominant and most fatal type of brain tumor in adults. The prognosis of GBM remains poor despite advances in surgery, chemotherapy and radiotherapy. It is common that patients with GBM exhibit innate or acquired resistance to temozolomide (TMZ), a standard chemotherapeutic agent for GBM, and a previous report demonstrated that miRNA‑233 (miR‑223) promotes the growth and invasion of GBM cells by targeting tumor suppressor paired box 6 (PAX6). The present study explored the effect of TMZ on miR‑223/PAX6 signaling in addition to the effect of miR‑223/PAX6 signaling on TMZ chemoresistance in human GBM cells...
December 27, 2016: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28034663/acute-liver-injury-induced-by-levetiracetam-and-temozolomide-co-treatment
#6
Tawfik Khoury, Shmuel Chen, Ayman Abu Rmeileh, Saleh Daher, Shaul Yaari, Ariel A Benson, Jonah Cohen, Meir Mizrahi
BACKGROUND: Temozolomide (TMZ) is an alkylating agent used for treatment of brain neoplasms and levetiracetam (LEV) is a commonly used antiepileptic. When administered separately each medication has few negative side effects impacting the liver. AIMS: We sought to determine the risk of liver injury associated with the co-administration of TMZ and LEV. METHODS: A case-control study was performed comparing patients who received combination therapy of TMZ and LEV (group A) with matched controls (group B) who received monotherapy with one of either TMZ or LEV...
December 5, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28031240/combination-of-a-stat3-inhibitor-and-an-mtor-inhibitor-against-a-temozolomide-resistant-glioblastoma-cell-line
#7
Haruo Miyata, Tadashi Ashizawa, Akira Iizuka, Ryota Kondou, Chizu Nonomura, Takashi Sugino, Kenichi Urakami, Akira Asai, Nakamasa Hayashi, Koichi Mitsuya, Yoko Nakasu, Ken Yamaguchi, Yasuto Akiyama
BACKGROUND: Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed. MATERIALS AND METHODS: The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ-resistant U87 cell line. RESULTS: The growth-inhibitory effect of the combination treatment was significant against the TMZ-R U87 cell line (IC50: 78 μM for STX-0119, 30...
January 2017: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/28011051/a-phase-2-trial-of-neoadjuvant-temozolomide-followed-by-hypofractionated-accelerated-radiation-therapy-with-concurrent-and-adjuvant-temozolomide-for-patients-with-glioblastoma
#8
George Shenouda, Luis Souhami, Kevin Petrecca, Scott Owen, Valerie Panet-Raymond, Marie-Christine Guiot, Andrea Gomez Corredor, Bassam Abdulkarim
PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy. METHODS AND MATERIALS: Adult patients with newly diagnosed glioblastoma and a Karnofsky Performance Status >60 were eligible...
November 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28007652/characteristics-of-sulfasalazine-induced-cytotoxicity-in-c6-rat-glioma-cells
#9
Raffaela Silvestre Ignarro, Gustavo Facchini, Daniela Rodrigues de Melo, Karin Juliane Pelizzaro-Rocha, Carmen Veríssima Ferreira, Roger Frigério Castilho, Fabio Rogerio
Glioblastoma is the most aggressive primary brain tumor. Surgical resection, radiotherapy and temozolomide (TMZ), an alkylating agent, is the standard of care. Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS). C6 rat glioma cells are largely used in in vitro and in vivo models for developing new glioblastoma treatment strategies. We treated C6 cells with 25μM TMZ and/or 0.25mM or 0.5mM SAS for 1, 3 or 5days and evaluated viability, apoptosis, total glutathione levels and metalloproteinase MMP2 and MMP9 activities...
December 19, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/27994066/phase-iii-randomized-study-of-radiation-and-temozolomide-versus-radiation-and-nitrosourea-therapy-for-anaplastic-astrocytoma-results-of-nrg-oncology-rtog-9813
#10
Susan Chang, Peixin Zhang, J Gregory Cairncross, Mark R Gilbert, Jean-Paul Bahary, Carol A Dolinskas, Arnab Chakravarti, Kenneth D Aldape, Erica H Bell, David Schiff, Kurt Jaeckle, Paul D Brown, Geoffrey R Barger, Maria Werner-Wasik, Helen Shih, David Brachman, Marta Penas-Prado, H Ian Robins, Karl Belanger, Christopher Schultz, Grant Hunter, Minesh Mehta
BACKGROUND: The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU). Secondary endpoints were time to tumor progression (TTP), toxicity, and the effect of IDH1 mutation status on clinical outcome. METHODS: Eligible patients with centrally reviewed, histologically confirmed, newly diagnosed AA were randomized to receive either RT+TMZ (n = 97) or RT+NU (n = 99)...
December 18, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27986595/the-chac1-inhibited-notch3-pathway-is-involved-in-temozolomide-induced-glioma-cytotoxicity
#11
Peng-Hsu Chen, Wan-Lin Shen, Chwen-Ming Shih, Kuo-Hao Ho, Chia-Hsiung Cheng, Cheng-Wei Lin, Chin-Cheng Lee, Ann-Jeng Liu, Ku-Chung Chen
Glioblastoma multiforme (GBM) is the high-grade primary glioma in adults. Temozolomide (TMZ), an alkylating agent of the imidazotetrazine series, is a first-line chemotherapeutic drug for clinical therapy. However, the expense of TMZ therapy and increasing drug resistance to TMZ decreases its therapeutic effects. Therefore, our aim was to investigate the detailed molecular mechanisms of TMZ-mediated cytotoxicity to enhance the efficacy of TMZ in clinical GBM therapy. First, TMZ-mediated gene expression profiles and networks in U87-MG cells were identified by transcriptome microarray and bioinformatic analyses...
December 13, 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27975145/dynamic-contrast-enhanced-mr-imaging-in-predicting-progression-of-enhancing-lesions-persisting-after-standard-treatment-in-glioblastoma-patients-a-prospective-study
#12
Roh-Eul Yoo, Seung Hong Choi, Tae Min Kim, Chul-Kee Park, Sung-Hye Park, Jae-Kyung Won, Il Han Kim, Soon Tae Lee, Hye Jeong Choi, Sung-Hye You, Koung Mi Kang, Tae Jin Yun, Ji-Hoon Kim, Chul-Ho Sohn
OBJECTIVES: To prospectively explore the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting the progression of enhancing lesions persisting after standard treatment in patients with surgically resected glioblastoma (GBM). METHODS: Forty-seven GBM patients, who underwent near-total tumorectomy followed by concurrent chemoradiation therapy (CCRT) with temozolomide (TMZ) between May 2014 and February 2016, were enrolled. Twenty-four patients were finally analyzed for measurable enhancing lesions persisting after standard treatment...
December 14, 2016: European Radiology
https://www.readbyqxmd.com/read/27959385/microtubule-actin-cross-linking-factor-1-a-novel-target-in-glioblastoma
#13
Najlaa Afghani, Toral Mehta, Jialiang Wang, Nan Tang, Omar Skalli, Quincy A Quick
Genetic heterogeneity is recognized as a major contributing factor of glioblastoma resistance to clinical treatment modalities and consequently low overall survival rates. This genetic diversity results in variations in protein expression, both intratumorally and between individual glioblastoma patients. In this regard, the spectraplakin protein, microtubule actin cross-linking factor 1 (MACF1), was examined in glioblastoma. An expression analysis of MACF1 in various types of brain tumor tissue revealed that MACF1 was predominately present in grade III-IV astroctyomas and grade IV glioblastoma, but not in normal brain tissue, normal human astrocytes and lower grade brain tumors...
January 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/27942839/immune-modulation-associated-with-vascular-endothelial-growth-factor-vegf-blockade-in-patients-with-glioblastoma
#14
Alissa A Thomas, Jan L Fisher, Thomas H Hampton, Brock C Christensen, Gregory J Tsongalis, Gilbert J Rahme, Chery A Whipple, Sandra E Steel, Melissa C Davis, Arti B Gaur, Lionel D Lewis, Marc S Ernstoff, Camilo E Fadul
BACKGROUND: Vascular endothelial growth factor (VEGF), in addition to being pro-angiogenic, is an immunomodulatory cytokine systemically and in the tumor microenvironment. We previously reported the immunomodulatory effects of radiation and temozolomide (TMZ) in newly diagnosed glioblastoma. This study aimed to assess changes in peripheral blood mononuclear cell (PBMC) populations, plasma cytokines, and growth factor concentrations following treatment with radiation, TMZ, and bevacizumab (BEV)...
December 9, 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27941537/autophagy-inhibitors-chloroqiune-and-ly294002-enhance-temozolomide-cytotoxicity-on-cutaneous-melanoma-cell-lines-in-vitro
#15
Oxana O Ryabaya, Andrey N Inshakov, Angelina V Egorova, Marina A Emelyanova, Tatiana V Nasedkina, Alexander S Zasedatelev, Dmitry A Khochenkov, Evgenia V Stepanova
Patients with metastatic melanoma are difficult to treat and have a very poor prognosis because of high resistance to therapy. Recent evidence indicates that tumors could overcome death through autophagy, a survival mechanism, which cancer cells use under lack of energy and nutrient deprivation. Melanoma cells have different sensitivity to temozolomide (TMZ) treatment. In this study, we showed that the combination of autophagy inhibitors chloroquine or LY294002 and TMZ induced enhanced cytotoxicity of alkylating agents on human melanoma cell lines...
December 9, 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27936607/ph-sensitive-o6-benzylguanosine-polymer-modified-magnetic-nanoparticles-for-treatment-of-glioblastomas
#16
Zachary R Stephen, Rachel N Gebhart, Mike Jeon, Allison A Blair, Richard G Ellenbogen, John R Silber, Miqin Zhang
Nanoparticle-mediated delivery of chemotherapeutics has demonstrated potential in improving anticancer efficacy by increasing serum half-life and providing tissue specificity and controlled drug release to improve biodistribution of hydrophobic chemotherapeutics. However, suboptimal drug loading, particularly for solid core nanoparticles (NPs), remains a challenge that limits their clinical application. In this study we formulated a NP coated with a pH-sensitive polymer of O(6)-methylguanine-DNA methyltransferase (MGMT) inhibitor analog, dialdehyde modified O(6)-benzylguanosine (DABGS) to achieve high drug loading, and polyethylene glycol (PEG) to ameliorate water solubility and maintain NP stability...
December 12, 2016: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/27933657/analysis-of-temozolomide-resistance-in-low-grade-gliomas-by-using-a-mechanistic-mathematical-model
#17
Edouard Ollier, Pauline Mazzocco, Damien Ricard, Gentian Kaloshi, Ahmed Idbaih, Agusti Alentorn, Dimitri Psimaras, Jérôme Honnorat, Jean-Yves Delattre, Emmanuel Grenier, François Ducray, Adeline Samson
Understanding how tumours develop resistance to chemotherapy is a major issue in oncology. When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting. In addition, it has been suggested that TMZ may drive tumour progression in a subset of patients as a result of acquired resistance. Using longitudinal tumour size measurements from 121 patients, the aim of the present study was to develop a semi-mechanistic mathematical model to determine whether resistance of LGG to TMZ was more likely to result from primary and/or from chemotherapy-induced acquired resistance that may contribute to tumour progression...
December 9, 2016: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/27931804/evaluation-of-the-mutagenicity-of-alkylating-agents-methylnitrosourea-and-temozolomide-using-the-rat-pig-a-assay-with-total-red-blood-cells-or-reticulocytes
#18
Shigeharu Muto, Katsuya Yamada, Tatsuya Kato, Masamitsu Ando, Yoshimi Inoue, Yumiko Iwase, Yoshifumi Uno
A collaborative study of the endogenous phosphatidylinositol glycan class A (Pig-a) gene mutation assay was conducted by the Japanese Environmental Mutagen Society/Mammalian Mutagenicity Study Group with a single-dosing regimen of test chemicals administered to male rats. As a part of the study, two DNA alkylating agents, methylnitrosourea (MNU) and temozolomide (TMZ), were dosed by single oral gavage at 25, 50, and 100mg/kg body weight. Pig-a mutant analysis of total red blood cells (RBCs; RBC Pig-a assay) and reticulocytes (RETs; PIGRET assay) was performed on Days 8, 15 and 29 after the administration...
November 15, 2016: Mutation Research
https://www.readbyqxmd.com/read/27931551/metabolic-manipulation-in-dilated-cardiomyopathy-assessing-the-role-of-trimetazidine
#19
Suman Jatain, Aditya Kapoor, Archana Sinha, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel
OBJECTIVES: To study the role of metabolic modulator (trimetazidine: TMZ) in dilated cardiomyopathy (DCM). Optimizing altered substrate metabolism in heart failure (HF) with metabolic modulators allows more efficacious energy production from glucose than from free fatty acids. METHODS: 100 patients of DCM (47.7 years, NYHA class 2.17, LVEF 27.3%) were randomized to TMZ (20mg tid, n=50) vs conventional therapy (n=50). Functional status, BNP and various echocardiographic parameters were assessed at 3-6 months...
November 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27921166/outcome-in-unresectable-glioblastoma-mgmt-promoter-methylation-makes-the-difference
#20
Niklas Thon, Jun Thorsteinsdottir, Sabina Eigenbrod, Ulrich Schüller, Jürgen Lutz, Simone Kreth, Claus Belka, Jörg-Christian Tonn, Maximilian Niyazi, Friedrich Wilhelm Kreth
In 2011, we reported a predominant prognostic/predictive role of MGMT promoter methylation status on progression-free survival (PFS) in unresectable glioblastoma patients undergoing upfront radiotherapy plus concomitant and maintenance temozolomide (RTX/TMZ → TMZ). We, here, present the final results of this prospective study focussing on the prognostic/predictive value of MGMT promoter methylation status for death risk stratification. Overall, 56 adult patients with unresectable, biopsy proven glioblastoma were prospectively assigned to upfront RTX/TMZ → TMZ treatment between March 2006 and August 2008...
December 5, 2016: Journal of Neurology
keyword
keyword
40515
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"